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 Abstract   
 
Background: Inflammatory bowel disease (IBD) is a poorly understood process that affects over 
a million people in the United States alone. The disease typically manifests as recurrent flares of 
abdominal pain and bloody diarrhea along with periods of remission. Standard therapy has 
focused around maintenance and remission, rather than a cure. These lifelong diagnoses carry 
devastating consequences for patients. Modern medical therapy consists primarily of steroids, 
aminosalicylate anti-inflammatories and immunomodulators.  
 
Irritable Bowel Syndrome (IBS) is one of the most common diagnoses in gastroenterology 
practices in the North American hemisphere. IBS shares many of the same symptoms as IBD and 
despite growing research and compelling data, it’s still unclear if there are genetic components 
and mucosal changes to explore.  
 
Patients are becoming increasingly interested in how to maintain their remission or reverse the 
disease processes through diet and lifestyle changes. Current research focused on the chemical 
compound curcumin, found in the Turmeric rhizome, may hold the keys to maintaining 
remission in mild to moderate ulcerative colitis (UC). Through systematic literature review this 
article aims to explore existing research regarding natural food-based compounds, namely 
curcumin, and the potential benefits for patients with IBD and IBS diagnoses.    
 
Methods:  An exhaustive search of available medical literature using the following databases: 
MEDLINE-PubMed, CINAHL-EBSCO Host and Web of Science was performed using the 
keywords “inflammatory bowel disease” and “curcumin.” Randomized controlled trials (RCTs) 
were selected and inclusion criteria required studies from the past 5 years. Studies were assessed 
for quality using GRADE criteria. 
 
Results: An extensive review of the studies concluded that there was no harm in using curcumin 
as add on therapy for IBD and while one study showed inconclusive improvement in inducing 
remission of patients with mild to moderate UC, the other showed improvement for patients 
suffering from IBS, which is characterized by the lack of inflammatory process but presence of 
unexplained cramping, gastrointestinal (GI) distress and either constipation or diarrhea. Many, if 
not all, of the symptoms of IBS are present in patients suffering from Inflammatory Bowel 
Diseases. The strongest support for alternative IBD therapy regarding curcumin is for remission 
maintenance in people with mild to moderate UC. 
 
Conclusion:  Although there is not enough current evidence to conclude that curcumin alone can 
induce or maintain remission in IBD patients; with the current available data it appears that there 
may be symptomatic relief along with negligible risk for patients looking outside of standard 
maintenance therapies.  
 
Keywords:  Inflammatory Bowel Disease, Irritable Bowel Syndrome, Crohn’s Disease, Crohns, 
Ulcerative Colitis, UC, Curcumin, Curcuminoid, Turmeric, Curcuma longa, Flares, Colon 
Cancer, Indian, Curry, Gastrointestinal, Mesalamine 
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Curcumin as an Aid to Improve Symptoms of 
Inflammatory or Irritable Bowel Diseases 
BACKGROUND 
It is known that curcumin (diferuloyl methane), a compound found in the Curcuma 
Longa or turmeric plant, possesses anti-inflammatory properties that have been shown to 
alleviate some of the symptomatology associated with Inflammatory Bowel Disease (IBD), 
specifically when maintaining remission in mild to moderate Ulcerative Colitis (UC).1,2 IBD is a 
broad term used to describe vaguely understood autoimmune inflammation of the gastrointestinal 
(GI) tract. The 2 diseases associated with IBD are Crohn’s disease (CD) (effecting any or all of 
the small and large bowel) or Ulcerative Colitis (UC) (disease isolated to the colon and rectum).3 
Irritable Bowel Syndrome (IBS) is associated with many of the same indicia as diseases 
like UC and CD, but it lacks drastic changes to the colonic mucosa and is recognized as a 
motility disorder that causes bloating and flatulence, along with constipation, diarrhea or mixed 
IBS.4 The differences and similarities between IBS and IBD have been studied since the late 
1970s, early 1980s.5 IBS accounts for as much as half of GI visits in the US and is more common 
than IBD.6 While the pathophysiology of IBS and IBD have traditionally been viewed as 
separate conditions; It’s frivolous to overlook the reality that an IBD patient in remission will 
often experience IBS symptoms.7 There is evidence citing that IBS colonic mucosa does have an 
element of low-grade inflammation.8 For this reason, both the Portincasa et al9 and Singla et al10 
studies were chosen as the RCTs to evaluate the effectiveness of the curcumin compound on IBD 
symptomatology. A difference to be noted between IBD and IBS is that a diagnosis of IBS has 
not shown to increase the risk of mortality or colon cancer; a diagnosis of IBD, likely due to 
chronic states of inflammation, does have increased morbidity and mortality risks.11 
UC is a debilitating, lifelong, relapsing-remitting IBD that afflicts millions of individuals 
throughout the world and produces symptoms that impair quality of life (QOL) and the ability to 
function.12 As previously mentioned, while IBS and IBD are very different disease states (one 
does not lead to the other), some of the physical manifestations are similar and both have shown 
some benefit from curcumin therapy in the form of symptomatic relief.  
Symptoms of IBD and IBS include some form of chronic or persistent abdominal 
cramping, pain, diarrhea, constipation, mucus in the stool, gassiness and/or constipation 
alternating with diarrhea. Symptoms specific to IBD include anemia, abdominal pain and 
cramping, weight loss, fever and bloody diarrhea. A comparison of IBD and IBS is found in 
Table 1.13,14,15,16   
The prevalence of IBD in the United States varies by geographical region and is more 
predominant in more industrialized nations.17 CD and UC carry large burdens on the healthcare 
system. Frequent lapses in remission, despite long-term medical therapies, account for a large 
number of hospitalizations.2 Accepted therapies for UC patients are long-term mesalamine or 
sulfasalazine (5-ASA) protocols with corticosteroids for flares, possible immunosuppressive 
monoclonal antibody agents and azathioprine (6-MP). Initially effective, most agents fail over 
time and the patient must graduate up to a stronger or different treatment options.2 Each of these 
medications comes with an extensive list of adverse effects, ranging from Cushing’s syndrome 
from long-term steroid use to lymphoma and pancreatitis from 6-MP.18 If treatments continue to 
fail without remission, surgery becomes inevitable. Current research is targeted at finding a 
compound to induce and/or maintain remission. Curcumin may have a protective role in IBD 
through modulation of the release of interleukin 6 (IL-6), tissue necrosis factor-alpha (TNF 
alpha), myeloperoxidase (MPO) and nitric oxide.2 
The Lang et al study found that in patients with mild to moderate UC, curcumin, in 
addition to mesalamine therapy, was statistically superior at inducing remission compared to 
patients on mesalamine alone.19  
Along with anti-inflammatory properties, curcumin has been studied for its antioxidant 
properties and the potential to influence signaling pathways like the kinases (MAPK, ERK), 
cycloxygenase 1 and 2 (COX-1 and COX-2), lipoxygenase (LOX) and inhibiting the 
transcription factor nuclear factor kappl-light-chain-enhancer (NF-kB).20 
There is varying research in regards to the bioavailability of curcumin, choice of delivery 
method and its efficacy against IBD, IBS and colon cancer cells.  
It cannot be determined what method of drug delivery, if any, might induce remission for 
IBD patients. There is evidence that curcumin may help to maintain remission for UC patients 
and relieve symptomatology for IBS patients.2 
A major hurdle for scientists has been finding ways to make the curcumin compound 
bioavailable and pharmacologically effective against targeted cells. The polyphenol has a rapid 
metabolism, is photosensitive and water-soluble.21 It’s been discovered that when conjugated 
with poly(lactic-co-glycolic acid) (PLGA), curcumin becomes a sustainable compound with anti-
proliferative activity and apoptosis in human CC cells.22 
With IBD numbers on the rise in industrialized nations, it’s not surprising that colon 
cancer or large bowel cancer is more common as well.17,23 India, categorized by some experts as 
an industrialized nation, has drastically lower incidence rates of colon cancer than the United 
States.24 This phenomenon is more prevalent in rural areas and is attributed to a traditional diet 
consisting of starches and curcumin used in Indian cooking.23 
With a number of drugs on the market to treat IBS and IBD, but none that are sufficient 
in curing the symptoms, or inducing/maintaining remission, (especially barring adverse effects), 
the question remains: Can Curcumin aid in improving symptoms in patients with mild to 
moderate IBD or IBS? 
METHODS 
An exhaustive literature search was done using MEDLINE-PubMed, CINAHL-EBSCO 
host and Web of Science using the keywords: “inflammatory bowel disease” and “curcumin.” 
Both key terms were then limited to Randomized Control Studies and restricted to English 
language. Further filters included human only and studies published within the last 5 years. 
Studies were assessed using GRADE criteria.25 
RESULTS 
The initial search using MEDLINE-PubMed yielded 32 articles. CINHAL-EBSCO 
yielded 3 articles and Web of Science yielded 56 for a total of 91 search results. Using PICO for 
inclusion and exclusion criteria, it was narrowed down to 2 randomized control studies9,10 (See 
Table 2).  
Portincasa et al 
Study Description –The first of 2 randomized placebo-controlled studies was published 
in 2016 in the Journal of Gastrointestinal Liver Disease, examining 121 patients with mild-to-
moderate IBS symptoms defined by the Irritable Bowel Syndrome Symptom Severity Score 
(IBS-SSS) and a Visual Analogue Scale (VAS). Patients >18 years old and <60 years old were 
recruited within a randomized, double-blind, placebo-controlled trial involving 5 different 
centers in Italy. All patients were given a Rome III diagnosis of IBS (62% were IBS-Diarrhea 
subjects and 38% were IBS-Constipation subjects). Patients received 2 capsules of either 
Curcumin 42 mg and Fennel essential oil 25 mg (CU-FEO) or placebo under fasting conditions. 
Patients had to have an IBS-SSS between 100-300 points for at least 3 of 10 days preceding 
enrollment, plus the symptom of abdominal distention or dissatisfaction of bowel habits.  
Patients with IBD, structural abnormalities of the GI tract, history of alcohol or drug 
abuse, positive stool cultures for pathogenic bacteria, moderate to severe liver or heart disease, 
biliary tract obstruction, previous surgeries in the last 6 months, mental illness or other 
immunological, hematological or neoplastic diseases were excluded.  
The study screened and forbade use of non-steroidal anti-inflammatories, anticoagulants, 
antibiotics, fibers and prebiotics two weeks prior to, and throughout the duration of the trial. In a 
controlled and detailed fashion, the study allowed patients to use antispasmodics, motility 
regulating drugs, laxatives, anti-depressant and anti-anxiolytics. Acetaminophen could be used, 
but no longer than three consecutive days. The consumption of concomitant drugs was 
reportedly: controlled, minimal and comparable9 between the two groups at each point in the 
study.  
Participants were evaluated and given a validated IBS-SSS questionnaire, along with a 
QOL questionnaire four times throughout the study; day 0 (or baseline), day 10, day 20 and day 
30 (the end of the study). Scoring of the two questionnaires were statistically combined and 
compared between the two groups of participants.  
The baseline characteristics for the study groups included: age, sex, severity of disease 
(mild vs. moderate), IBS-SSS (evaluating: abdominal pain, number of days without pain, 
abdominal distension, dissatisfaction with bowel habit and interference with QOL) and a 
combined IBS-QOL score.  
Study Results –Out of the 121 patient participants who began the study, 116 finished. 2 
(one placebo and one non-placebo) were excluded because they didn’t take the product, 2 (one 
placebo and one non-placebo) withdrew consent before they could be assessed post-baseline, and 
one patient from the placebo group withdrew consent due to worsening esophageal reflux like 
symptoms 10 days into placebo treatment.  
Overall, this study shows that curcumin-fennel (CU-FEO) significantly improved 
symptoms and QOL in IBS patients.9 (see Figure 1). Patients with IBS were given oral CU-FEO 
in capsule form for 30 days. Patients were evaluated via questionnaire at baseline (day 0), days 
10, 20 and 30. Fennel essential oil was used along with the curcumin due to its known 
carminative effects. The study found significant improvement in overall QOL of subjects using 
CU-FEO versus placebo.9   
Between the two groups, placebo and non-placebo, baseline characteristics showed 
mainly female participants with an average age of 40 and an IBS-SSS ranging from 143-300. 
The overall baseline IBS-QOL was comparable between the two treatment groups (52.1±20.8 
and 53.3±20 in CU-FEO and placebo group, respectively).9  
There was a statistically relevant decrease in the mean IBS-SSS scores. Compared to 
baseline, patients who took the CU-FEO decreased from 255.7±39.9 to 127.8±77.4 (range 0 – 
300) by day 30. While the placebo group saw some improvement 263.2±34.4 to 195.5±88.0 
(range 25 - 345), the relative decrease was significantly greater and almost double with CU-FEO 
compared to placebo at day 30 (the end of the trial).  
Patients taking CU-FEO achieved higher and statistically significant levels of complete 
symptom free relief and a greater than 50% reduction in abdominal pain symptom score 
compared to placebo groups.  
Statistically the CU-FEO group saw significant improvement by day 10 in the abdominal 
distension category by 10, and the others followed by days 20 and 30. At the end of treatment, 30 
days, the IBS-QoL total score was significantly greater in the CU-FEO than in placebo group 
(17.4±19.2 vs. 7.7±18.0, respectively; P = 0.003) with an adjusted mean difference between 
groups of 9.19 (95% CI: 3.13, 15.25).9  
Singla et al 
A systematic review from the Cochrane Database published in 2012 found that there is 
evidence that it may be helpful to add oral curcumin therapy to 5-ASA in patients with mild to 
moderate colitis in order to maintain remission.2 The Singla et al study aimed to further 
investigate and support this evidence.  
Study Description –The Singla et al study, targeted at mild-to-moderate distal UC, used 
a curcumin enema delivery method in adjunct with patients’ currently dosed oral 5-ASA. Disease 
activity was assessed during individualized visits at weeks 0, 4 and 8.  
Participants were all >18 years of age, had mild-to-moderate distal UC based on the 
Ulcerative Colitis Disease Activity Index (UCDAI) score,26 had 25 cm of diseased colon from 
the anal verge and were on a stable dose of Mesalamine therapy for more than 8 weeks.  
Individual scores were added to the 4 parameters included in UCDAI which are: bowel 
frequency, rectal bleeding, endoscopic exam and physician’s rating of severity. Patients were 
asked about rectal bleeding and stool frequency and given scores in regards to his or her reported 
symptoms over the past 7 days. These criteria were assessed and scored at weeks 0, 4 and 8.   
Exclusions were made for patients who had used rectal steroids or rectal 5-ASA in the 4 
weeks preceding the trial. Patients with severe UC based on the UCDAI score and those who’s 
5-ASA therapy was either initiated in the last 3 months or adjusted in the preceding 8 weeks 
were not included. Patients with recent hospital stays, steroid injections or initiations those on 
investigational medicines, along with those patients with significant hepatic, renal, endocrine, 
respiratory and cardiovascular disease were excluded.  
Patients were given either placebo enemas or enemas with 140 mg of NCB-02 (the 
standardized extract of Curcuma Longa) dissolved in 20 ml of water. The composition was 72% 
curcumin, 18.08% demethoxy curcumin and 9.42% bis-demethoxy curcumin.10 All patients also 
received 800 mg oral mesalamine twice daily for the duration of the study.  
Study Results – 45 patients met inclusion criteria and consented for this study and were 
randomized. 23 received NCB-02, 22 received placebo. Only 14 patients in the NCB-02 group 
and 16 in the placebo group finished the study.  In the NCB-02 group, 5 had worsening 
symptoms and 4 were lost during follow-up evaluation. In the placebo group, 4 patients had 
worsening symptoms and had to drop out, and 2 were lost during follow-up.  
Although the mesalamine use and age and sex were comparable in the two groups, the 
NCB-02 group had a significantly higher number of patients who had been treated with steroids 
in the past, as well as the duration of the disease compared to placebo groups.  
While more patients receiving the curcumin NCB-02 enema (than the placebo group) 
improved after 8 weeks, the difference was not statistically significant. At the end of the trial, the  
NCB-02 group saw a higher response to treatment. More patients were in remission in the NCB-
02 group than in the placebo group, and a higher number of patients received proved endoscopic 
disease activity scores in the NCB-02 group than the placebo.   
The methodologies and improved outcomes appear promising, but further studies with 
more participants need to be done on the subject.10 
 
DISCUSSION 
Providers should not hesitate to recommend the addition of curcumin, in plant or essential 
oil form, for patients suffering from IBD or IBS. If curcumin additive is not tolerated it should be 
discontinued immediately as any positive therapeutic effect is outweighed by adverse reaction(s). 
The current research is not sufficient to suggest that curcumin will induce remission for a patient, 
but it is promising that CU-FEO may reduce IBS symptoms and oral curcumin can aid in 
maintaining remission and/or lessening flares for IBD patients.9,2,19  
Neither of the studies addressed Crohn’s disease, found under the IBD umbrella. In a 
pilot study done in 200527 patients with Crohn’s and distal UC, or proctitis were given curcumin 
to test its anti-inflammatory processes. 4 out of the 5 Crohn’s patients and 5 out of the 5 proctitis 
patients showed some form of relief. The point is there is promising reason to believe that the 
anti-inflammatory, anti-oxidative and analgesic properties found in the turmeric rhizome of the 
Cucuma Longa plant must continue to be studied in different populations.  
None of these studies does an adequate job addressing the subject of curcumin’s 
bioavailability. Curcumin has a rapid plasma clearance and conjugation. If the curcumin is not 
bioavailable, the patient will not be able to appreciate its systemic effects. Oral curcuminoids can 
be combined with the alkaloid piperine (found in black pepper) in order to be adequately 
absorbed and considered bioavailable.28  
Adding turmeric (the rhizome containing curcumin compounds) to the diet may introduce 
anti-inflammatory, anti-oxidative properties to combat colon cancer.29 While there is no direct 
evidence citing turmeric or curry-based foods as colon-protective anti-cancer therapy, there is no 
harm in following in the footsteps of countries like pre-industrialized India. Before rising obesity 
rates, and diets rich in fruits and vegetables became unpopular, India touted one of the lowest 
colorectal cancer rates in the world.30 
Important flaws to note are the small trial sizes and the vague nature of this clinical 
question. Providers cannot be confident in this limited amount of research that curcumin alone 
induces or maintains remission of IBD. While it may aid relief of symptoms there is still much to 
be answered.  
Method of delivery needs to be further explored by future research, particularly in human 
subjects. Should providers be suggesting Turmeric Enemas to their patients? Not at this time. As 
previously mentioned, there will likely never be an RCT where patients stop the use of remission 
therapy and take turmeric alone, making this a difficult subject to research.  
CONCLUSION 
While there seems to be some favorable evidence that curcumin can aid in the relief of 
IBD and IBS symptomatology, the current research is minimal and needs to be added upon. 
Focus on lifestyle changes, particularly diet and exercise, is the current recommendation for add-
on therapy and there is no harm in the addition of low-cost, easily accessible alternatives like 
turmeric for patient treatment plans. In summation, curcumin in your diet can’t hurt, but it may 
help. In a Westernized culture where obesity, weakly understood autoimmune processes and 
cancer are on the rise, research must expand and continue for the betterment of medical efficacy 
and treatment plans worldwide.  
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 Table 2: Quality Assessment of Reviewed Articles 
Study 
Desig
n 
Downgrade Criteria Upgra
de 
Criteri
a 
Quality Limitatio
ns 
Indirectn
ess 
Inconsisten
cy 
Imprecisi
on 
Publicati
on bias 
Portinca
sa et al9 
RCT Not 
Serious 
Seriousa Not 
Serious 
Seriousa Unlikely None Modera
te 
Singla 
et al10 
RCT Not 
Serious 
Seriousc Not 
Serious 
Seriousb Unlikely None Modera
te 
a The Portincasa et al study has a small cohort size (121 participants). 
b The Singla et al study size (45 participants). 
 
 
Table 1: Comparison of UC, CD 
and IBS 
Ulcerative Colitis Both CD 
& UC 
Crohn’s disease  Both IBD 
& IBS 
Irritable Bowel Syndrome  
Epidemiology 
Sex Ratio (M:F) 
 
Nicotine 
 
Genetic Components 
 
 
1:1 
 
May be protective  
 
 
Yes 
 
 
 
 
 
 
* 
 
2:1 
 
Can Precipitate 
CD 
 
Yes 
 
 
 
* 
 
 
* 
 
More prevalent in women than 
men  
 
Risk factor for developing IBS14 
 
Some Familial Tendency13 
Clinical Manifestations 
Hematochezia 
 
Mucus in Rectum 
 
Small Bowel Involvement 
 
Upper GI tract involvement 
 
Abdominal Cramping 
 
Abdominal Pain 
 
Increased bloating 
 
Excessive Flatulence  
 
Diarrhea and Constipation 
 
Possible Skin, Bone and Joint 
Manifestations 
 
Yes 
 
Yes 
 
No 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
* 
 
* 
 
 
 
 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
Less Common 
 
Less Common 
 
Yes  
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
 
 
 
 
 
 
 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
No 
 
No 
 
No 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
Biochemical Findings 
Genetic Components 
 
ANCA-Positive 
 
ASCA-Positive  
 
Yes 
 
More Common 
 
Less Common 
 
* 
 
Yes 
 
Less Common 
 
More Common 
 
 
 
Feasible, needs further 
investigation16 
Histopathology  
Acute and Chronic Inflammation 
 
Mucosal Involvement 
 
Granulomas and Serositis 
 
Cryptitis  
 
Fissures or Skip Lesions 
 
Proximally diffuse 
 
Transmucosal 
 
Very Rare 
 
Yes 
 
Very Rare 
 
* 
 
* 
 
* 
 
* 
 
* 
 
Focal 
 
Transmural 
 
Common 
 
Yes 
 
Common 
 
 
 
* 
 
 
 
Some studies have showed 
increased numbers of activated 
immunocompetent cells in the 
intestinal mucosa on quantitative 
immunohistology, implicating the 
mucosal immune system in 
pathogenesis.15 
FIGURE 1 PORTINCASA 
 
 
 
